文献速递胸部肿瘤

KRAS突变及共突变对III期非鳞NSCLC放化疗联合免疫治疗结局的影响

Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.
PubMed 文献 · J Thorac Oncol · 2026-01-29

该多中心回顾性分析纳入208例接受根治性同步放化疗后度伐利尤单抗治疗的III期非鳞NSCLC患者,比较KRAS突变型与野生型患者的结局。KRAS突变型患者中位PFS更短(16 vs 28个月,p=0.024),远处转移(2年44% vs 34%,p=0.042)和脑转移发生率更高(p=0.007)。KRAS突变合并CDKN2A或STK11共突变者PFS最差。

要点

  • KRAS突变型III期非鳞NSCLC同步放化疗后度伐利尤单抗治疗PFS更短。
  • KRAS突变与远处转移和脑转移发生率升高相关。
  • CDKN2A或STK11共突变提示更差PFS,支持评估KRAS抑制剂。

核心结论

  • KRAS突变型III期非鳞NSCLC接受同步放化疗后度伐利尤单抗治疗结局更差,主要由远处转移和脑转移增加驱动。
  • 合并CDKN2A或STK11共突变的KRAS突变肿瘤结局最差。

研究设计与样本

  • 多中心回顾性分析纳入208例接受根治性同步放化疗后度伐利尤单抗治疗的III期非鳞NSCLC患者。
  • 117例为KRAS野生型,91例为KRAS突变型;对接受下一代测序的患者评估共突变对PFS的影响。

主要发现

  • KRAS突变型患者中位PFS为16个月,KRAS野生型为28个月(p=0.024)。
  • KRAS突变与更差PFS在单变量和多变量分析中均相关。
  • KRAS突变型患者2年远处转移发生率为44%,野生型为34%(p=0.042)。
  • KRAS突变型患者脑转移发生率更高(p=0.007)。
  • KRAS突变合并CDKN2A或STK11共突变者PFS较KRAS野生型更差,而无CDKN2A或STK11共突变的KRAS突变者无此差异。

临床怎么用

  • 对III期非鳞NSCLC患者可考虑检测KRAS及CDKN2A/STK11共突变以识别高危人群。
  • KRAS突变尤其合并CDKN2A或STK11共突变者预后差,需加强远处转移和脑转移监测。
  • 该高危人群可考虑纳入KRAS抑制剂相关临床研究评估。

局限性

  • 回顾性设计可能存在选择偏倚。
  • 共突变分析仅限接受下一代测序的患者,样本量可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Outcomes in unresected locally advanced NSCLC (LA-NSCLC) are poor despite improvement with immunotherapy after concurrent chemoradiation (cCRT). Although KRAS is the most common mutated oncogene in NSCLC, its impact on outcomes in LA-NSCLC treated with cCRT and durvalumab remains underexplored. METHODS: We conducted a multicenter retrospective analysis of patients with stage III nonsquamous NSCLC treated with definitive cCRT followed by durvalumab. Progression-free survival (PFS) and incidence of distant metastasis and locoregional recurrence were compared by KRAS status. Of patients who underwent next-generation sequencing, we assessed the impact of co-alterations on PFS. RESULTS: Among 208 consecutive patients, 117 had KRAS wild-type (WT) and 91 had KRAS-mutant disease. Median PFS was shorter for those with KRAS-mutant disease compared with those with KRAS WT (16 versus 28 mo, p = 0.024). KRAS mutations were associated with worse PFS on univariable and multivariable analyses. There was an increased incidence of distant metastasis for patients with KRAS-mutant disease compared with patients with KRAS WT disease (2 y, 44% versus 34%, p = 0.042), including increased brain metastasis incidence (p = 0.007). Among KRAS-mutant tumors, co-alterations with CDKN2A or STK11 were associated with worse PFS compared with KRAS WT, whereas KRAS mutations without CDKN2A or STK11 co-alterations were not. CONCLUSIONS: KRAS-mutant nonsquamous LA-NSCLC is associated with inferior outcomes, largely driven by increased distant and brain metastases. Tumors with concurrent CDKN2A or STK11 alterations had the poorest outcomes. These findings support the evaluation of KRAS inhibitors in this high-risk stage III population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Mankuzhy NP, Santo V, Shin JY, et al. Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy. J Thorac Oncol. 2026. PMID: 41619904. doi:10.1016/j.jtho.2026.103565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。